The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Vaccines, Blood & Biologics
Our STN: BL 125391/0
Attention: Sharon Miller
12635 East Montview Blvd, Suite 300
Aurora, Colorado 80045
Dear Ms. Miller:
We received your January 31, 2012 amendment to your biologics license application (BLA) submitted under section 351 of the Public Health Service Act (42 U.S.C. 262) for Hematopoietic Progenitor Cells, Cord (HPC-C) on February 1, 2012.
We consider your submission a major amendment under the reauthorization of the prescription drug user fee program in the Food and Drug Administration Amendments Act of 2007.
Because we received this major amendment within three months of the action due date, we will add an additional three months to the time by which we should complete our review. Therefore, the action due date is June 2, 2012.
If you have any questions, please contact the Regulatory Project Manager, Ramani Sista, at (301) 827-5152.
Raj K. Puri, M.D., Ph.D.
Division of Cellular and Gene Therapies
Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and Research